Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors
- 1 April 1982
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 7 (2-3) , 113-115
- https://doi.org/10.1007/bf00254531
Abstract
Summary In order to determine if any inherent sensitivity differences may exist between VP16-213 and VM26 individual human tumors were grown in vitro and drug sensitivities were determined using the soft agar clonogenic assay method. Only nine of the 34 tumors tested so far showed a differing sensitivity to VP16-213 and VM26 as measured by a 25% or greater colony number reduction. However in none of these tumors did this added reduction result in a 70% decrease over control plate colony numbers. As yet we have been unable to demonstrate any clinically meaningful inherent in vitro sensitivity difference between VP16-213 and VM26 in any tumor type tested.Keywords
This publication has 7 references indexed in Scilit:
- Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapyThe American Journal of Medicine, 1981
- IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPYThe Lancet, 1980
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer DrugsNew England Journal of Medicine, 1978
- DIRECT CLONING OF HUMAN OVARIAN CARCINOMA CELLS IN AGAR1978
- Primary Bioassay of Human Tumor Stem CellsScience, 1977
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesPublished by Elsevier ,1975